135 related articles for article (PubMed ID: 28736245)
21. Long term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva.
Haviv R; Zeitlin L; Moshe V; Ziv A; Rabinowicz N; De Benedetti F; Prencipe G; Matteo V; De Cunto CL; Hsiao EC; Uziel Y
Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38733591
[TBL] [Abstract][Full Text] [Related]
22. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.
Di Rocco M; Forleo-Neto E; Pignolo RJ; Keen R; Orcel P; Funck-Brentano T; Roux C; Kolta S; Madeo A; Bubbear JS; Tabarkiewicz J; Szczepanek M; Bachiller-Corral J; Cheung AM; Dahir KM; Botman E; Raijmakers PG; Al Mukaddam M; Tile L; Portal-Celhay C; Sarkar N; Hou P; Musser BJ; Boyapati A; Mohammadi K; Mellis SJ; Rankin AJ; Economides AN; Trotter DG; Herman GA; O'Meara SJ; DelGizzi R; Weinreich DM; Yancopoulos GD; Eekhoff EMW; Kaplan FS
Nat Med; 2023 Oct; 29(10):2615-2624. PubMed ID: 37770652
[TBL] [Abstract][Full Text] [Related]
23. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists.
Shimono K; Tung WE; Macolino C; Chi AH; Didizian JH; Mundy C; Chandraratna RA; Mishina Y; Enomoto-Iwamoto M; Pacifici M; Iwamoto M
Nat Med; 2011 Apr; 17(4):454-60. PubMed ID: 21460849
[TBL] [Abstract][Full Text] [Related]
24. Garetosmab in Fibrodysplasia Ossificans Progressiva: Clinical Pharmacology Results from the Phase 2 LUMINA-1 Trial.
Wang Y; Nguyen JH; de Ruiter RD; Mendell J; Srinivasan D; Davis JD; Eekhoff EMW
J Clin Pharmacol; 2024 Feb; 64(2):264-274. PubMed ID: 37694449
[TBL] [Abstract][Full Text] [Related]
25. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.
Katagiri T; Tsukamoto S; Kuratani M
Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575
[TBL] [Abstract][Full Text] [Related]
26. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
Upadhyay J; Xie L; Huang L; Das N; Stewart RC; Lyon MC; Palmer K; Rajamani S; Graul C; Lobo M; Wellman TJ; Soares EJ; Silva MD; Hesterman J; Wang L; Wen X; Qian X; Nannuru K; Idone V; Murphy AJ; Economides AN; Hatsell SJ
J Bone Miner Res; 2017 Dec; 32(12):2489-2499. PubMed ID: 28782882
[TBL] [Abstract][Full Text] [Related]
27. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.
Hino K; Horigome K; Nishio M; Komura S; Nagata S; Zhao C; Jin Y; Kawakami K; Yamada Y; Ohta A; Toguchida J; Ikeya M
J Clin Invest; 2017 Sep; 127(9):3339-3352. PubMed ID: 28758906
[TBL] [Abstract][Full Text] [Related]
28. Atypical presentation and management of fibrodysplasia ossificans progressiva.
Grenho A; Arcângelo J; Martins A
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28751434
[TBL] [Abstract][Full Text] [Related]
29. Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.
Han HJ; Jain P; Resnick AC
Bone; 2018 Apr; 109():91-100. PubMed ID: 28780023
[TBL] [Abstract][Full Text] [Related]
30. Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.
Du Z; Yu Y; Wu D; Zhang G; Wang Y; He L; Meng R
Medicine (Baltimore); 2018 Nov; 97(45):e13105. PubMed ID: 30407323
[TBL] [Abstract][Full Text] [Related]
31. Clinical-pathological correlations in three patients with fibrodysplasia ossificans progressiva.
Wentworth KL; Bigay K; Chan TV; Ho JP; Morales BM; Connor J; Brooks E; Shahriar Salamat M; Sanchez HC; Wool G; Pignolo RJ; Kaplan FS; Hsiao EC
Bone; 2018 Apr; 109():104-110. PubMed ID: 29033382
[TBL] [Abstract][Full Text] [Related]
32. Imaging assessment of fibrodysplasia ossificans progressiva: Qualitative, quantitative and questionable.
Al Mukaddam M; Rajapakse CS; Pignolo RJ; Kaplan FS; Smith SE
Bone; 2018 Apr; 109():147-152. PubMed ID: 28822792
[TBL] [Abstract][Full Text] [Related]
33. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
Muranaka T; Kuwatani M; Komatsu Y; Sawada K; Nakatsumi H; Kawamoto Y; Yuki S; Kubota Y; Kubo K; Kawahata S; Kawakubo K; Kawakami H; Sakamoto N
J Gastrointest Oncol; 2017 Jun; 8(3):566-571. PubMed ID: 28736643
[TBL] [Abstract][Full Text] [Related]
34. Two new risk factors for heterotopic ossification development after severe burns.
Thefenne L; de Brier G; Leclerc T; Jourdan C; Nicolas C; Truffaut S; Lapeyre E; Genet F
PLoS One; 2017; 12(8):e0182303. PubMed ID: 28777823
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
36. Nivolumab for the treatment of bladder cancer.
Hakenberg OW
Expert Opin Biol Ther; 2017 Oct; 17(10):1309-1315. PubMed ID: 28737430
[TBL] [Abstract][Full Text] [Related]
37. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia.
Curtis SA; Curtis BR; Lee AI; Hendrickson JE; Lacy J; Podoltsev NA
Hematology; 2018 Aug; 23(7):429-432. PubMed ID: 29281948
[TBL] [Abstract][Full Text] [Related]
38. Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
Kaplan FS; Zeitlin L; Dunn SP; Benor S; Hagin D; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():281-284. PubMed ID: 29241828
[TBL] [Abstract][Full Text] [Related]
39. Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial.
Pacifici M
Bone; 2018 Apr; 109():267-275. PubMed ID: 28826842
[TBL] [Abstract][Full Text] [Related]
40. PEMETREXED-INDUCED PSEUDOCELLULITIS - A RARE CUTANEOUS ADVERSE REACTION TO MULTI-TARGETED ANTIFOLATE THERAPY.
Wollina U; Hansel G; Zschuppe E; Tchernev G
Georgian Med News; 2017 Jun; (267):81-84. PubMed ID: 28745612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
